Should SPDR S&P 600 Small Cap ETF (SLY) Be on Your Investing Radar?

10:20am, Tuesday, 29'th Mar 2022 Zacks Investment Research
Style Box ETF report for SLY

Should iShares Core S&P SmallCap ETF (IJR) Be on Your Investing Radar?

10:20am, Thursday, 24'th Mar 2022 Zacks Investment Research
Style Box ETF report for IJR

Should Vanguard S&P SmallCap 600 ETF (VIOO) Be on Your Investing Radar?

10:20am, Wednesday, 23'rd Mar 2022 Zacks Investment Research
Style Box ETF report for VIOO

Phreesia (PHR) Soars 5.9%: Is Further Upside Left in the Stock?

07:52am, Thursday, 17'th Mar 2022 Zacks Investment Research
Phreesia (PHR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in

Omnicell (OMCL) Down 5.6% Since Last Earnings Report: Can It Rebound?

03:30pm, Wednesday, 16'th Mar 2022 Zacks Investment Research
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock?

Should iShares S&P SmallCap 600 Growth ETF (IJT) Be on Your Investing Radar?

11:20am, Tuesday, 01'st Mar 2022 Zacks Investment Research
Style Box ETF report for IJT

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

11:20am, Tuesday, 01'st Mar 2022 Zacks Investment Research
Sector ETF report for PSCH

CHNG vs. OMCL: Which Stock Is the Better Value Option?

04:40pm, Monday, 28'th Feb 2022 Zacks Investment Research
CHNG vs. OMCL: Which Stock Is the Better Value Option?
CHNG vs. OMCL: Which Stock Is the Better Value Option?

Should SPDR S&P 600 Small Cap Growth ETF (SLYG) Be on Your Investing Radar?

11:20am, Wednesday, 23'rd Feb 2022 Zacks Investment Research
Style Box ETF report for SLYG

Should Vanguard S&P SmallCap 600 Growth ETF (VIOG) Be on Your Investing Radar?

11:20am, Thursday, 17'th Feb 2022 Zacks Investment Research
Style Box ETF report for VIOG
Recording the biggest intraday decline since March 2020, the shares of Omnicell <> have approached an eight-month low after the med-tech company set its 2022 earnings guidance…

Omnicell (OMCL) Q4 Earnings Miss Estimates, Revenues Beat

02:48pm, Tuesday, 15'th Feb 2022 Zacks Investment Research
Robust performance by the Product and Service segments is driving Omnicell's (OMCL) fourth-quarter top line.
Omnicell Inc''s (NASDAQ: OMCL ) Q4 sales increased 25% Y/Y to $311.0 million , compared to the consensus of $311 million. The increase reflects strong demand for Omnicell''s medication management adherence automation solutions and the contribution of revenues from the acquisition of RxInnovation Inc , operating as FDS Amplicare . The company posted an adjusted EPS of $0.92 in line with the consensus. Adjusted EBITDA was $52.0 million, compared to $51.6 million in Q4 … Full story available on Benzinga.com
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE